Klebsiella Infections - Pipeline Insight, 2024

This “Klebsiella Infections - Pipeline Insight, 2024” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Klebsiella Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Klebsiella Infections: Understanding

Klebsiella Infections: Overview

Klebsiella is a type of bacteria commonly found in nature. In humans, the bacteria are often present in parts of the digestive tract where they do not generally cause problems. In the United States, Klebsiella pneumoniae and Klebsiella oxytoca are the two strains responsible for most human illnesses. Many Klebsiella infections are acquired in the hospital setting or in long-term care facilities. In fact, Klebsiellae account for up to 8% of all hospital-acquired infections. People with a compromised immune system and/or people who have an implanted medical device (such as a urinary catheter or airway tube) are more at risk for Klebsiella infections. Extensive use of antibiotics has resulted in the development of antibiotic-resistant strains of Klebsiella. These infections can be more aggressive and difficult to treat.

The causes of Klebsiella pneumoniae transmission these germs don’t spread through the air there is a need direct contact to get sick. One way would be to touch a cut on skin with dirty hands. Most Klebsiella pneumoniae transmission happens in hospitals, nursing homes, and other places with lots of sick people. Health care workers can spread the germs if they don't wash and sanitize their hands often. The germs can also spread when they get on medical devices like: IV tubes that go into a vein to give medicines Endotracheal tubes and ventilators, which help to breathe and urinary catheters, which drain pee away when not able to use the bathroom.

The symptoms of Klebsiella pneumoniae infection depend on what part of body these germs have invaded. Symptoms of Klebsiella pneumonia includes fever, cough, chest pain, trouble breathing, reddish, jelly-like mucus. Klebsiella Pneumoniae diagnosis involves the doctor can do a number of tests to diagnose pneumonia or other infections caused by Klebsiella pneumoniae. Depending on what kind of infection the person have, they may test the blood, sputum (a mix of saliva and mucus that may cough up), pee the doctor may also use some kind of imaging, such as a chest X-ray, to help diagnose Klebsiella pneumoniae infection.

Antibiotics are the main treatment for Klebsiella pneumoniae infections. The doctor will send the blood, urine, sputum, or other body fluid to a lab to find out which antibiotic is the best one to treat the infection. Doctor will start treatment as soon as they learn which antibiotic the person should take. Examples include either a cephalosporin (such as cefepime) or a fluoroquinolone (such as ciprofloxacin) by themselves, or one of these antibiotics combined with an aminoglycoside.

Klebsiella Infections - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Klebsiella Infections pipeline landscape is provided which includes the disease overview and Klebsiella Infections treatment guidelines. The assessment part of the report embraces, in depth Klebsiella Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Klebsiella Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Klebsiella Infections R&D. The therapies under development are focused on novel approaches to treat/improve Klebsiella Infections.

Klebsiella Infections Emerging Drugs Chapters

This segment of the Klebsiella Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Klebsiella Infections Emerging Drugs

NOSO-502: Nosopharm NOSO-502 is nosopharm’s first clinical candidate in the new class of antibiotics called odilorhabdins and discovered from a XENORHABDUS BACTERIA. NOSO-502 is intended for the treatment of the main hospital-acquired infections caused by the multidrug-resistant Enterobacteriaceae; Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp. NOSO-502 inhibits the bacterial ribosome with a new mechanism of action. It is active against the Carbapenem-Resistant Enterobacteriaceae (CRE), whatever their profile of carbapenemase production. These pathogens are responsible for severe and life-threatening hospital-acquired infections. Currently the drug is in preclinical stage of development for the treatment of Klebsiellainfections.

Debio 1454: Debiopharm Debio 1454 is being developed to target a combination of enteric bacterial species including A. baumannii, Enterobacter Spp., Klebsiella pneumoniae and E.coli. In 2019, Debiopharm was awarded funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) in the US to advance the development of the Debio 1454 antibiotic program targeting the multidrug resistant superbug A. baumannii, a principal cause of highly resistant nosocomial-pneumonia and one of the priority 1 critical pathogens identified by the WHO. Currently the drug is in discovery stage of development for the treatment of Klebsiellainfections.

Klebsiella Infections: Therapeutic Assessment

This segment of the report provides insights about the different Klebsiella Infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Klebsiella Infections

• There are approx. 7+ key companies which are developing the therapies for Klebsiella Infections. The companies which have their Klebsiella Infections drug candidates in the most advanced stage, i.e. phase III include, Nosopharm.

Phases

This report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Klebsiella Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Klebsiella Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Klebsiella Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Klebsiella Infections drugs.

Klebsiella Infections Report Insights

• Klebsiella Infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Klebsiella Infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Klebsiella Infections drugs?
• How many Klebsiella Infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Klebsiella Infections?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Klebsiella Infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Klebsiella Infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Nosopharm
• Debiopharm
• Locus Biosciences, Inc.
• Inventprise

Key Products

• NOSO-502
• Debio 1454
• LBP-KP01
• IVT Klebsiella

This product will be delivered within 2 business days.